Company Oxis International OTC Bulletin Board
Equities
US6918295014
Pharmaceuticals
Business Summary
The group has a portfolio of 3 products in clinical development phase (GTB-3550, GTB-3650 and GTB-5550; treatment of leukemia and solid tumors).
Managers
Managers | Title | Age | Since |
---|---|---|---|
Michael Breen
CEO | Chief Executive Officer | 61 | 12/01/21 |
Manu Ohri
DFI | Director of Finance/CFO | 68 | 17/02/22 |
Jeffrey Miller
PRN | Corporate Officer/Principal | - | 13/12/22 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 78 | 30/04/23 | |
Bruce Wendel
BRD | Director/Board Member | 70 | 10/11/20 |
Rajesh Shrotriya
BRD | Director/Board Member | 79 | 12/01/21 |
Michael Breen
CEO | Chief Executive Officer | 61 | 12/01/21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 96,230 | 0 | 0 | 89.34 % |
Stock B | 1 | 2,156,651 | 2,012,830 ( 93.33 %) | 0 |
Company contact information
GT Biopharma, Inc.
8000 Marina Boulevard Suite 100
94005, Brisbane
+415 919 4040
http://www.gtbiopharma.comSector
1st Jan change | Capi. | |
---|---|---|
+45.82% | 765B | |
+40.95% | 632B | |
-6.16% | 354B | |
+19.86% | 331B | |
+9.32% | 299B | |
+18.45% | 248B | |
-0.78% | 219B | |
+11.88% | 216B | |
+5.90% | 164B |